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Abstract
Background: Single-dose human ﬁbrinogen concentrate (FCH) might have haemostatic beneﬁts in complex cardiovascular
surgery.
Methods: Patients undergoing elective aortic surgery requiring cardiopulmonary bypass were randomly assigned to receive
FCH or placebo. Study medication was administered to patients with a 5 min bleeding mass of 60–250 g after separation from
bypass and surgical haemostasis. A standardized algorithm for allogeneic blood product transfusion was followed if bleeding
continued after study medication.
Results: 519 patients from 34 centres were randomized, of whom 152 (29%)met inclusion criteria for studymedication. Median
(IQR) pretreatment 5 min bleedingmass was 107 (76–138) and 91 (71–112) g in the FCH and placebo groups, respectively (P=0.13).
More allogeneic blood product units were administered during the ﬁrst 24 h after FCH, 5.0 (2.0–11.0), when compared with
placebo, 3.0 (0.0–7.0), P=0.026. Fewer patients avoided transfusion in the FCH group (15.4%) compared with placebo (28.4%),
P=0.047. The FCH immediately increased plasma ﬁbrinogen concentration and ﬁbrin-based clot strength. Adverse event rates
were comparable in each group.
Conclusions: Human ﬁbrinogen concentrate was associated with increased allogeneic blood product transfusion, an
unexpected ﬁnding contrary to previous studies. Human ﬁbrinogen concentrate may not be effective in this setting when
administered according to 5-minute bleeding mass. Low bleeding rates and normal-range plasma ﬁbrinogen concentrations
before study medication, and variability in adherence to the complex transfusion algorithm, may have contributed to these
results.
Clinical trial registration: ClinicalTrials.gov identiﬁer no. NCT01475669; EudraCT trial no. 2011-002685-20.
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Editor’s key points
• Hypoﬁbrinogenaemia is a common occurrence after com-
plex cardiac surgery.
• There is variability in transfusion practices around the
world.
• Factor concentrates and other haemostatic agents are com-
monly used in complex cardiovascular surgery.
• This study found that ﬁbrinogen concentrate administra-
tion was associated with an increase in administration of
blood products.
Complex cardiovascular surgery with cardiopulmonary bypass
(CPB) is frequently associated with coagulopathy and bleeding.1
Allogeneic blood products are commonly administered despite
the inherent risks of transfusion-related acute lung injury, vol-
ume overload, and transmission of pathogens.2 3 Compared
with allogeneic blood products, coagulation factor concentrates
may reduce transfusion volumes and immunogenic or infectious
complications; they do not need cross-matching; and they can be
prepared and infused more rapidly.4 5
The pathophysiology of bleeding after cardiovascular surgery
and CPB is complex. Cardiopulmonary bypass causes greater
impairment of ﬁbrin formation than of thrombin generation or
platelet function.6 Fibrinogen is the ﬁrst coagulation factor to
reach critically low concentrations in major bleeding,7 which
has been associated with increased bleeding and adverse out-
comes in cardiovascular surgery and trauma.8–10 Thus, ﬁbrino-
gen is thought to have a key role in the management of bleeding.
Pasteurized human ﬁbrinogen concentrate (FCH) has been
available since 1985, and more than 3 million grams have been
administered.11 It is licensed in 18 countries for treatment and
prophylaxis of bleeding in patients with acquired hypoﬁbrino-
genaemia.12 Human ﬁbrinogen concentrate rapidly and consist-
ently increases plasma ﬁbrinogen concentrations, improving
clot strength and speed of clot formation.13 14
Initial investigations showed that FCH reduces transfusion in
aortic surgery requiring CPB,15 16 leading to a phase II, single-
centre, double-blind, placebo-controlled trial.17 18 The results of
that study demonstrated the potential for FCH to reduce bleeding
and transfusion in aortic replacement surgery.18 A multicentre
phase III study was designed with methodology based on the
phase II study. Based on results of the phase II study, the hypoth-
esis was that FCH decreases bleeding independent of the pa-
tient’s ﬁbrinogen concentration, and consequently, reduces
administration of allogeneic blood products compared with pla-
cebo. Our objective was to conﬁrm that FCH therapy reduces the
need for transfusion among complex cardiovascular surgery pa-
tients with a need for coagulation therapy to control bleeding but
no conﬁrmation of low plasma ﬁbrinogen concentrations.
Methods
Study design and population
This was a phase III, multinational, multicentre, randomized,
double-blind, placebo-controlled study (ClinicalTrials.gov identi-
ﬁer no. NCT01475669; EudraCT trial no. 2011-002685-20). The ﬁrst
patient was enrolled on January 23, 2012; the last patient com-
pleted the study on September 11, 2014. The study followed the
International Conference on Harmonization Good Clinical Prac-
tice guidelines. Patients were enrolled at 34 centres in 11 coun-
tries. At each centre, approval was obtained from the ethics
committee or institutional review board. Signed informed con-
sent was obtained from patients before participation. A protocol
amendment was implemented during the study (Supplementary
data, Table S1).
The inclusion criteria at screening were as follows: age ≥18 yr
(≥20 yr in Japan); and an elective open surgical procedure on any
part of the aorta requiring CPB, with or without other cardiac pro-
cedures. Exclusion criteria (Supplementary data, Table S2) in-
cluded the following: reoperative aortic surgery at the same site
as the original procedure; operation for infection; and any
known coagulation disorder.
At the start of surgery, patients were randomly assigned 1:1 to
receive FCH or placebo using an interactive voice response sys-
tem. Randomizationwas stratiﬁed by study centre and by surgery
(primary or reoperation).
To be eligible for study treatment, randomized patients had to
meet the following intraoperative inclusion criteria: ﬁrst 5 min
bleeding mass of 60–250 g; body temperature ≥35°C; activated
clotting time within 25% of the baseline value; and blood pH
>7.3. The 5 min bleeding mass was deﬁned as weight gained by
surgical swabs after 5 min of packing of the surgical site; it was
initially measured after surgical haemostasis was completed
after separation from CPB and heparin reversal. Intraoperative
exclusion criteria were as follows: prior use of any haemostatic
therapy during the surgical procedure; and any perception that
study participation could threaten the patient’s safety.
Study assessments were scheduled at screening (within
4 weeks before surgery; Visit 1), surgery (Day 1; Visit 2), discharge
from hospital or Day 11 (whichever was sooner; Visit 3), and end
of study (Day 46; Visit 4). Baseline characteristics were recorded
<48 h before surgery.
Procedures
Study medication [FCH (CSL Behring, Marburg, Germany) or pla-
cebo (0.9% sodium chloride solution)] was infused i.v. during 1–2
min. The dose of FCH was based on FIBTEMmaximum clot ﬁrm-
ness (MCF) at the end of CPB, targeting a FIBTEMMCF of 22mm.13
18 Study medication was prepared by a pharmacist or blood bank
technologist. The FCH was reconstituted with 50 ml sterile water
per gram of ﬁbrinogen. Investigator blinding was maintained by
providing placebo at an equivalent volume to the patient’s dose
of FCH and by using identical opaque syringes. Surgical, anaes-
thesia, and intensive care unit teams were blinded to ﬁbrinogen
concentrations and the results of ROTEM® (Tem International,
Munich, Germany) analyses throughout the study after adminis-
tration of study medication. The 5 min bleeding mass was as-
sessed for the second time approximately 5–10 min after
administration of study medication. A standardized transfusion
algorithm was followed if this was ≥60 g (Supplementary data,
Fig. S1). The 5 min bleedingmass wasmeasured after each trans-
fusion step, with further transfusions being administered if
bleedingmass remained≥60 g. Red blood cellswere administered
to patients with haemoglobin <7 g dl−1, end-organ ischaemia,
acute blood loss, or other patient-speciﬁc reasons. Antiﬁbrinoly-
tic medication could be given during surgery, according to each
site’s standard procedure. Administration of hydroxyethyl
starch, desmopressin, or aprotininwas not permitted during sur-
gery or within 24 h after study medication. The CPB pump was
primed using crystalloid ﬂuid.
Study end points
The primary end point was the number of units of allogeneic
blood products (FFP, platelets, and red blood cells) administered
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during the 24 h after administration of studymedication. Second-
ary end points included the number of units of individual allo-
geneic blood products, total avoidance of transfusions, need for
reoperation, mortality, plasma ﬁbrinogen (central laboratory,
Clauss assay), and MCF (FIBTEM assay performed at each site
using a ROTEM device). Safety was assessed principally by the in-
cidence of treatment-emergent adverse events (TEAEs) through-
out the 46 day observation period, changes in vital signs and
laboratory values, and ECG assessments. Viral transmission
was investigated by enzyme-linked immunosorbent assays and
polymerase chain reaction tests. The TEAEs of special interest in-
cluded thromboembolic events, allergic reactions to study medi-
cation, adverse effects of transfusions, and severe complications
of surgery or CPB. All serious adverse events (AEs) were moni-
tored by an independent Data Safety Monitoring Board; all fatal
and thromboembolic events were adjudicated by an independ-
ent, blinded adjudication committee.
Statistics
Sample sizewas calculated using aWilcoxon rank-sum superior-
ity test comparing allogeneic blood product use with FCH vs
placebo, with the following assumptions based on the phase II
trial: mean treatment difference, 7.12 ( 12.45) units; 5% of pa-
tients in the intention-to-treat analysis with primary efﬁcacy re-
sults imputed because of missing data, two-sided signiﬁcance
level of 5%; 90% power; randomization ratio 1:1; and distribution-
al assumptions for a parametric test not met. It was determined
that 152 patients would be required.
Efﬁcacy analysis was performed on the intention-to-treat
population, comprising all randomized patients who received
studymedication (identical to the safety population). Imputation
was performed for patients dying, withdrawing, or lost to follow-
up before 24 h after study medication, before discharge from
hospital, or before discharge from the intensive care unit. The
imputation procedure assigned the highest observed value in
the treatment group for the number of units of allogeneic blood
products and duration of hospitalization and intensive care
unit stay.
The primary efﬁcacy analysis compared median numbers of
units of allogeneic blood products by study group. Given the
low numbers of patients per study centre, instead of using
a stratiﬁed Wilcoxon test (van Elteren test) with stratiﬁcation
by study centre, pooled centres were created within countries
Patients enrolled
n=579
Patients failed post-enrolment screening
n=60
Patients not treated
n=367
• Failure to meet intraoperative criteria
  (n=331,of whom 322 did not meet
  5-minute bleeding mass inclusion
  criteria)
• Death (n=1)
• Adverse event other than death (n=3)
• Physician decision (n=9)
• Protocol violation (n=2)
• Subject withdrew consent (n=1)
• Other (n=20)
Patients randomized
n=519
Patients treated
n=152
Received FCH
n=78
Placebo
Discontinued study
n=6
• Death (n=5)
• Other (n=1)
FCH
Completed study
n=74
• ITT population
  (n=78)
• CTA population
  (n=48)
• Safety population
  (n=78)
Placebo
Completed study
n=68
• ITT population
  (n=74)
• CTA population
  (n=47)
• Safety population
  (n=74)
FCH
Discontinued study
n=4
• Death (n=1)
• Adverse events other than death (n=1)
• Subject withdrew consent (n=1)
• Other (n=1)
Received placebo
n=74
Fig 1 Patient disposition. CTA, completer of transfusion algorithm (i.e. patients in whom the standardized treatment algorithm was adhered to); FCH, human
ﬁbrinogen concentrate; ITT, intention to treat.
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with sufﬁcient patients (Canada, Czech Republic, Japan, and UK),
and the remaining countries (Austria, Denmark, Finland,
Germany, Italy, and Poland) were pooled together. For secondary
efﬁcacy analyses, continuous variables were analysed using a
Wilcoxon rank sum test with the same pooling of study centres.
Categorical variables were analysed by Cochran–Mantel–Haenszel
tests. Safety variableswere summarizedwith descriptive statistics
by treatment group. Results for variables following the normal
distribution are presented as the mean (), and variables not
following the normal distribution the results are presented as
the median [interquartile range (IQR)].
Results
Baseline and surgical characteristics
In total, 579 patients consented and were enrolled; of these, 519
were randomized. After conﬁrming fulﬁlment of the intraopera-
tive eligibility, 152 patients received studymedication (Fig. 1). The
most common procedure in both groups was thoracic aortic an-
eurysm repair with or without arch involvement. Of the 367 pa-
tients not receiving study medication, 327 (89%) had 5 min
bleeding mass <60 g. Most treated patients were male and of
white or Asian ethnicity (Table 1). One major difference between
study groups was that the initial 5 min bleeding mass (before
study medication) was higher in the FCH group than in the pla-
cebo group [median 107 (IQR 76–138) vs 91 (71–112) g, respectively;
P=0.13]. Otherwise, the groups were comparable. Intraoperative
and laboratory assessments were similar between the groups.
Efﬁcacy
The median decrease in 5 min bleeding mass between the ﬁrst
and second measurements was 20 (IQR 3.0–50) g in the FCH
group and 19.5 (1.0–42) g in the placebo group (P=0.32; Fig. 2 and
Table 2). The measurements of chest tube drainage at 6, 12, and
24 h after administration of studymedication showed numerical-
ly less bleeding in the FCH group (Table 2).
The primary analysis showed a median total of 5.0 (IQR2.0–
11.0) units of allogeneic blood products administered in the 24
h after study medication in the FCH group, compared with 3.0
(0.0–7.0) units in the placebo group (P=0.026; Fig. 3). In the FCH
group, values were imputed for two patients withdrawn from
the study within 24 h after receiving studymedication. Consider-
able variability in the primary end point was evident when com-
paring pooled study centres (Fig. 3).
Exploratory post hoc analyses of the primary end point were
performed with the following: (i) no imputation of missing data
(n=152); (ii) patients for whom the standardized transfusion algo-
rithm was followed (n=104); and (iii) patients for whom the stan-
dardized transfusion algorithm was not followed (n=48). The
results of analysis (i) were similar to those of the primary ana-
lysis. Median 24 h administration of allogeneic blood products
in population (iii) (FCH, 11.0 units; placebo, 8.0 units) was consid-
erably higher than that of population (ii) (FCH, 3.5 units; placebo,
1.0 units).
Additional efﬁcacy results were consistent with the primary
analysis (Table 2). The percentage of patients avoiding trans-
fusion of allogeneic blood products was higher in the placebo
group (21/74, 28.4% vs 12/78, 15.4%; P=0.047). Themedian number
of units of FFP transfused throughout the ﬁrst 24 h was signiﬁ-
cantly higher for the FCH group (P=0.017). Therewere no statistic-
ally signiﬁcant differences in transfusions of platelets or red
blood cells.
Sevenpatients (9.0%) in theFCHgroupand three (4.1%) in thepla-
cebo group required reoperation. Surgical bleeding was the reason
for reoperation in all of these patients except one in the FCH group.
Table 1 Baseline characteristics and perioperative data. *Before
the start of surgery. †Measured at the central laboratory.
‡Fibrinogen concentration at the time of measurement of the
ﬁrst 5 min bleeding mass, measured using the Clauss assay
(central laboratory). CPB, cardiopulmonary bypass; FCH, human
ﬁbrinogen concentrate; IQR, interquartile range;MCF,maximum
clot ﬁrmness; TAA, thoracic aortic aneurysm; TAAA, thoraco-
abdominal aortic aneurysm; TRUST, transfusion risk
understanding scoring tool
Parameter FCH (n=78) Placebo (n=74)
Sex [n (%)]
Female 18 (23.1) 23 (31.1)
Male 60 (76.9) 51 (68.9)
Age [yr; mean (range)] 63.9 (22–86) 64.2 (24–86)
BMI [kg m−2; mean ()] 25.7 (4.6) 25.6 (4.6)
Race [n (%)]
Asian 27 (34.6) 24 (32.4)
White 51 (65.4) 49 (66.2)
Other 0 1 (1.4)
Surgery type [n (%)]
TAAA repair 3 (3.8) 4 (5.4)
TAA repair with
proximal arch
32 (41.0) 36 (48.6)
TAA repair without
proximal arch
43 (55.1) 34 (45.9)
Unknown 0 3 (4.1)
TRUST score
Mean () 2.2 (1.42) 2.4 (1.59)
Plasma ﬁbrinogen* (g litre−1)
n 73 68
Mean () 3.03 (0.92) 3.06 (0.83)
FIBTEM MCF* (mm)
n 70 66
Mean () 16.3 (4.7) 16.5 (5.2)
Duration of CPB [n (%)]
<120 min 13 (16.7) 10 (13.5)
120–180 min 30 (38.5) 25 (33.8)
>180 min 35 (44.9) 39 (52.7)
Duration of circulatory arrest [n (%)]
0 53 (67.9) 41 (55.4)
>0 and <30 min 18 (23.1) 22 (29.7)
30–60 min 6 (7.7) 7 (9.5)
>60 min 1 (1.3) 4 (5.4)
Lowest core temperature (°C)
n 78 74
Mean () 28.8 (5.4) 28.1 (5.5)
First 5 min bleeding mass (g)
n 78 74
Median (IQR) 107.0 (76.0–138.0) 91.0 (71.0–112.0)
Platelet count at ﬁrst 5 min bleeding mass† (×109 litre−1)
n 70 69
Mean () 102.4 (48.76) 90.4 (35.7)
Last platelet count before administration of study medication
[n (%)]
<100×109 litre−1 38 (48.7) 38 (51.4)
≥100×109 litre−1 40 (51.3) 36 (48.6)
Plasma ﬁbrinogen before administration of study medication‡
(g litre−1)
n 74 70
Mean () 1.86 (0.66) 1.77 (0.51)
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The mean dose in the FCH group was 6.29 ( 1.97) g.
Treatment with FCH consistently achieved the target FIBTEM
MCF of 22 mm, corresponding to an immediate increase in the
plasma ﬁbrinogen concentration (Fig. 4). There was no increase
in the ﬁbrinogen concentration after administration of placebo.
The difference between the two treatment groups decreased as
time passed, and median plasma ﬁbrinogen concentrations
were similar in the two groups at Visit 3.
Further coagulation data (Supplementary data, Table S3)
show few differences between the two study groups in values
of coagulation factors or laboratory measures of coagulation, ei-
ther before or after study treatment. Pretreatment data suggest a
lack of pure coagulopathic bleeding in the study population. Post-
treatment ROTEM data for the FCH group show that, in addition
to increased strength of the ﬁbrin-based clot (FIBTEM MCF),
strength of the clot formed without platelet inhibition (EXTEM
MCF) was increased vs placebo, and that the speed of clot forma-
tion (clotting time and clot formation time in the EXTEM assay)
was increased.
Safety
Similar percentages of patients in both treatment groups re-
ported any TEAE, treatment-related TEAEs, and serious TEAEs
(Table 2). The most common TEAEs (≥20% in either group) were
atrial ﬁbrillation, pleural effusion, and anaemia (Supplementary
data, Table S4). Therewasno between-group difference in the fre-
quency of TEAEs of special interest or TEAEs related to study
medication (Supplementary data, Table S5).
Thromboembolic events were reported in 6/78 patients (7.7%)
in the FCH group and 10/74 patients (13.5%) in the placebo group.
No difference was apparent between the two groups in the type,
severity, or outcome of these events. No systematic differences
between groups were observed in vital signs, clinical chemistry,
haematology, or ECG assessments.
Six patients diedduring the study (FCH, one; placebo,ﬁve). Two
deaths (one per group) occurred between 1 and 10 days after study
medication; three (placebo) between 10 and 30 days; and one (pla-
cebo) occurred >30 days after study medication. Causes of death
were cerebrovascular accident (FCH group) and ischaemic cerebral
infarction, brain injury, infection, sepsis, and cardiac tamponade
(placebo group). All deaths except one (placebo) were considered
by the investigator as unrelated to study medication.
Discussion
REPLACE was the ﬁrst prospective, multinational, multicentre
phase III study assessing the effects of FCH on bleeding and
transfusion of allogeneic blood products in cardiovascular
250A
B
200
150
100
50
60 g
0
FCH 1st
FCH
Start CPB End CPB
190 min
(SD: 80 min)
26 min
(SD: 14 min)
13 min
(SD: 9 min)
1st 5-min
BM
79 min
(SD: 56 min)
3 minutes
(SD: 2 min)Study
treatment
2nd 5-min
BM
Skin
closure
FCH 2nd Placebo 1st
Placebo
Placebo 2nd
5-
m
in
u
te
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le
ed
in
g 
m
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s 
(g)
Fig 2 First and second bleeding mass (median, interquartile range and range; ) and the timings of these assessments [mean (); ]. BM, bleeding mass;
CPB, cardiopulmonary bypass; FCH, human ﬁbrinogen concentrate.
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surgery. When given to randomized patients as a single bolus
according to 5min bleedingmass, FCHwas associatedwith an in-
crease in administration of blood products. This unexpected ﬁnd-
ing, contrary to previous studies, might be attributable to low
bleeding rates, the fact thatmany patients had plasmaﬁbrinogen
concentrations that would not trigger therapy in clinical practice,
and variability in adherence to the complex transfusion algo-
rithm. Treatment with FCH achieved the target FIBTEM MCF
of 22 mm, reﬂecting an immediate, consistent increase in the
plasma ﬁbrinogen concentration that was not associated with
any adverse safety ﬁndings.
Previous single-centre studies of FCH as haemostatic therapy
in patients undergoing complex cardiovascular surgery reported
positive efﬁcacy results. Initial studies investigated FCH in
ascending aorta replacement and elective thoraco-abdominal
aortic aneurysm surgery, where a single bolus of ﬁbrinogen con-
centrate reduced the need for transfusion compared with the
control group.15 16 In the randomized, placebo-controlled,
single-centre phase II study, which the REPLACE study was
based upon, FCH reduced 24 h administration of allogeneic blood
products comparedwith placebo (median 2 vs 13 units, P<0.001).18
Humanﬁbrinogen concentrate also reduced transfusionamong29
coronaryartery bypass graft patientswith decreased platelet func-
tion.19 In amore recent study in 116 patients undergoing complex
cardiac surgery with CPB, avoidance of transfusions was achieved
in 67.2% of patients receiving ﬁrst-line treatment with FCH
(median dose 4 g), vs 44.8% in the placebo group.20
Our study was of a similar design to the preceding, single-
centre phase II study,18 but conducted in multiple centres in
different countries. Although the hypothesis that FCH leads to
a reduction in transfusion of allogeneic blood products in these
experimental conditions was rejected, evidence from other stud-
ies (including randomized controlled trials)13 15 16 18–21 shows this
effect. We do not have a deﬁnitive explanation for the difference
in results between REPLACE and the preceding phase II study but,
as discussed below, multiple factors may be considered. Future
studies of FCH in cardiac surgery would beneﬁt from efforts to
address these factors, and the lack of cell salvage data is a further
weakness of our study that could be addressed.
Variability
The inclusion of a large number of centres in multiple countries,
as opposed to the single-centre setting, allowed for increased
variability in clinical practice. There were differences among
countries and among centres within each country in the com-
plexity of surgical procedures, the extent to which study proce-
dures departed from routine practice, and in adherence to the
study protocol; all these could have inﬂuenced the study out-
come. As an example, the randomization failure rate (i.e. patients
not meeting the bleeding mass criterion) ranged from 18.7% in
Japan to 81.4% in the pooled centre. These increases in variability
increased the level of ‘noise’, making the detection of a treatment
effect less likely.
Table 2 Efﬁcacy and safety results. AE, adverse event; FCH, human ﬁbrinogen concentrate; FFP, fresh frozen plasma; IQR, interquartile range;
TEAE, treatment-emergent adverse event
Parameter FCH (n=78) Placebo (n=74) P-value
Primary end point
Total number of units of allogeneic blood product during ﬁrst 24 h after study medication
Median (IQR) 5.0 (2.0–11.0) 3.0 (0.0–7.0) 0.026
Secondary end points
Number of patients with total avoidance of allogeneic blood product transfusion
n (%) 12 (15.4) 21 (28.4) 0.047
Units of packed red blood cells administered (ﬁrst 24 h)
Median (IQR) 1.0 (0.0–3.0) 0.0 (0.0–2.0) 0.101
Units of FFP administered (ﬁrst 24 h)
Median (IQR) 4.0 (0.0–6.0) 0.0 (0.0–4.0) 0.017
Units of platelet concentrate administered (ﬁrst 24 h)
Median (IQR) 1.0 (0.0–2.0) 1.0 (0.0–1.0) 0.089
Blood loss after administration of study medication: 5 min bleeding mass (g)
Second 5 min bleeding mass [median (IQR)] 78.0 (55.0–110.0) 72.0 (45.0–96.0) 0.195
Decrease from ﬁrst 5 min bleeding mass [median (IQR)] 20.0 (3.0–50.0) 19.5 (1.0–42.0) 0.319
Blood loss after administration of study medication: chest tube drainage volume [ml; median (IQR)]
6 h 260.0 (155.0–410.0) 297.5 (200.0–455.0) 0.241
12 h 405.0 (245.0–600.0) 447.5 (320.0–700.0) 0.137
24 h 590.0 (400.5–839.5) 682.5 (530.0–1050.0) 0.120
Adverse events
Pretreatment AE 27 (34.6) 26 (35.1) –
Any TEAE 75 (96.2) 67 (90.5) –
Severe TEAE 42 (53.8) 38 (51.4) –
Treatment-related TEAE 10 (12.8) 10 (13.5) –
Serious TEAE 27 (34.6) 25 (33.8) –
Treatment-related serious TEAE 4 (5.1) 4 (5.4) –
TEAE leading to death 1 (1.3) 5 (6.8) –
TEAE of special interest 32 (41.0) 32 (43.2) –
TEAE leading to discontinuation 1 (1.3) 0 –
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Adherence to study protocol
Overall adherence to the transfusion algorithm was only 68% in
REPLACE (ranging across pooled centres from 100% in the Czech
Republic to 47.6% in Canada), compared with 87% in the preced-
ing phase II study (Supplementary data, Fig. S2). Allogeneic blood
product transfusion in instances where the algorithm was not
followed was three times higher than where the algorithm was
followed. The algorithm was designed speciﬁcally for use in
this study to demonstrate a treatment effect with FCH, and the
authors do not consider it to be applicable in routine clinical prac-
tice. It is possible that the algorithmwas too complex to follow in
the multicentre setting, particularly in patients with severe
bleeding. The high rate of non-adherence to the algorithm in-
creased variability in the primary end point (number of units
transfused). Although protocol deviations occurred to a similar
extent in both study groups, they differed between centres,
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increasing overall variability within the study and decreasing the
likelihood of detecting the true effect of FCH.
In REPLACE, the mean time from the end of CPB to the ﬁrst
5min bleedingmasswas prolonged: 25.6 ( 13.5) min, compared
with 11.3 (7.9) min in the phase II study. Surgical haemostasis
was likely to be ongoing during this period, leading to 62% of ran-
domized patients not fulﬁlling the bleeding criteria to receive
study medication. In the phase II study, only 19% of randomized
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patients failed tomeet the bleeding criteria. It is encouraging that
haemostasis could be achieved by surgical means alone in a sig-
niﬁcant proportion of patients. However, outside the conﬁnes of a
clinical trial, an increased tendency towards clinically signiﬁcant
bleeding is likely, and this would increase the need for procoagu-
lant therapy. Therefore, in the ‘real world’ setting, it is possible
that the treatment effect of FCH could be higher than in the clin-
ical trial setting. The time between the end of the ﬁrst and start of
the second 5 min bleeding mass measurement was also pro-
longed in REPLACE: 12.5 ( 9.4) min, compared with 8.1 (3.3)
min in the phase II study. The protocol stated that the second 5
min bleeding mass should have occurred immediately after
study drug infusion. Surgical haemostasis may have occurred
during the period between ﬁrst and second bleeding mass mea-
surements, and consequently, the second 5 min bleeding mass
may have provided a less accurate evaluation of the efﬁcacy of
studymedication in the REPLACE study. The differences between
REPLACE and the preceding phase II study in timings of study as-
sessments could have contributed to the differences in the ef-
fects of FCH on bleeding and transfusion of allogeneic blood
products.
Criteria for administering therapy
The use of 5min bleedingmass to assess bleeding and trigger the
administration of study drug must be questioned. The procedure
involved the surgeon packing swabs around suture lines to col-
lect blood and not suctioning any blood for 5 min, then weighing
the swabs to quantify blood collected. The surgical packing alone
may have reduced or stopped surgical bleeding, introducing po-
tential variability not accounted for in the study design. The arbi-
trary 5 min bleeding mass threshold of 60 gmay have aggravated
random pretreatment differences between the two groups. By
chance, patients in the placebo arm had a lower median ﬁrst
5-minute bleeding mass than those in the FCH group [91.0 g (IQR:
71.0–112.0 g) vs. 107.0 g (IQR: 76.0–138.0 g); P=0.134]. Thus, in the
placebo group, a smaller change in bleedingmasswas required to
meet the criteria for avoidance of transfusion (i.e. 5 min bleeding
mass <60 g). Although the median reduction in bleeding mass
was ∼20 g in both groups, avoidance of transfusion was higher
in the placebo group than in the FCH group (28.4 vs 15.4%). Future
research might identify a better method to assess bleeding while
the sternum is open and surgery is ongoing.
Fibrinogen supplementation is indicated in patients with hy-
poﬁbrinogenaemia. A single deﬁnition of hypoﬁbrinogenaemia
in this context is not universally agreed, but less than 1.5–2.0 g
litre−1 has been proposed. Our patients receiving FCH had a
mean pretreatment ﬁbrinogen concentration of 1.9 ( 0.66) g
litre−1; therefore, it is possible that the potential effect of FCH
was reduced. Based on results of the preceding phase II study,
we were not expecting an issue in this regard.
The safety results of REPLACE are consistent with previous
ﬁndings that FCH is well tolerated. No new safety concerns
emerged, and there was no increase in thromboembolic events
or mortality compared with placebo. The results are aligned
with published postmarketing safety surveillance data, showing
the incidences of all AEs and thromboembolic events to be 1 in
6200 and 1 in 23 300 standard doses, respectively.22
In conclusion, the administration of a single bolus of FCH to
treat bleeding after complex cardiac surgery, without selecting
patients by ﬁbrinogen concentration, was associated with an in-
crease in the transfusion of allogeneic blood products. The main
differencewas in transfusion of FFP rather than red cells or plate-
lets. The percentage of patientswith total avoidance of allogeneic
blood product transfusion was also lower in the FCH group than
in the placebo group. Considering that the mean plasma ﬁbrino-
gen concentration before FCH administration was relatively high
at 1.9 g litre−1, the use of 5 min bleeding mass to determine the
need for FCH administrationmust be questioned. Human ﬁbrino-
gen concentrate produced a rapid, consistent increase in plasma
ﬁbrinogen to the target value andwaswell tolerated. The primary
efﬁcacy ﬁnding of this study, which was not consistent with pre-
vious reports, does not answer the question whether FCH would
be efﬁcacious if given to correct low levels of ﬁbrinogen activity.
The highly variable environment of the multicentre setting and
elements of the study design that were applicable only in the
single-centre setting (e.g. complexity of the treatment algorithm)
might have contributed to the study outcome. Our results might
help the design of future studies.
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